Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.54 |
| ▸ | F10 | P00742 | 12/20 | 0.54 |
| ▸ | F7 | P08709 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 11/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.51 |
| ▸ | PLG | P00747 | 10/20 | 0.51 |
| ▸ | PLAT | P00750 | 9/20 | 0.51 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882746 | 1.00 | F2 (0.54) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL31364563 | 0.99 | F2 (0.53) | F2F10F7PLAUPRSS1 | |
| SCHEMBL2077857 | 0.91 | F2 (0.60) | F2F10F7PLAUPRSS1 | |
| SCHEMBL7408233 | 0.86 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23793906 | 0.84 | F2 (0.51) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL30387135 | 0.83 | F2 (0.50) | F2F10F7PLAUPRSS1 | |
| Hydrochloric Acid SCHEMBL28582608 | 0.83 | F2 (0.50) | F2F10F7PLAUPRSS1 | |
| SCHEMBL7405355 | 0.81 | F10 (0.51) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23775703 | 0.81 | F2 (0.55) | F2F10F7PLAUPRSS1 | |
| SCHEMBL23793904 | 0.81 | F10 (0.48) | F2F10F7PLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F2 4188/4885F10 4171/4885F7 4785/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4188/4885F10 4171/4885F7 4785/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | F2 36/4885F10 299/4885F7 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.